| Autor: |
Hakeam A. Hakeam, Ghadi Askar, Khalid Al Sulaiman, Reem Mansour, Maha M. Al Qahtani, Dana Abbara, Nada Aldhayyan, Nariman Dyab, Liyan Afaneh, Muna Islami, Zainab Al Duhailib |
| Jazyk: |
angličtina |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Journal of Infection and Public Health, Vol 15, Iss 10, Pp 1081-1088 (2022) |
| Druh dokumentu: |
article |
| ISSN: |
1876-0341 |
| DOI: |
10.1016/j.jiph.2022.08.020 |
| Popis: |
Background: Ceftolozane-tazobactam is an emerging treatment for severe infections caused by multidrug-resistant (MDR) Pseudomonas aeruginosa. However, limited data support its use in bacteremia treatment. This study aimed to assess the effectiveness of the treatment of MDR P. aeruginosa bacteremia using ceftolozane-tazobactam-based or colistin-based regimens. Patients and methods: This retrospective, cohort, multicentre study included adult patients with MDR P. aeruginosa bacteremia treated with either ceftolozane-tazobactam or colistin, between September 2018 and August 2021, at four hospitals in Saudi Arabia. The primary endpoint was the 30-day risk-adjusted mortality. Secondary endpoints included the 14-day risk of mortality, bacterial eradication, and clinical success. Cox proportional hazards regression and relative risk estimation were used for analysis, as appropriate. Results: In total, 46 patients were included; 17 patients received ceftolozane-tazobactam-based regimen, and 29 received a colistin-based regimen. There was no association with the use of ceftolozane-tazobactam compared to colistin and the 30-day risk-adjusted mortality (hazard ratio [HR] 0.58, 95% confidence interval [CI] 0.16–2.13, P = 0.42). Also, the 14-day risk of mortality and bacterial eradication were not different between the ceftolozane-tazobactam and colistin regimens, HR 2.1, 95% CI 0.42–10.48; P = 0.36; and relative risk (RR) 0.65; 95% CI 0.28–1.52; P = 0.30; respectively. On the other hand, ceftolozane-tazobactam use was associated with higher clinical success than colistin (RR 1.84, 95% CI 1.11–3.06: P = 0.021). Conclusion: The risk of mortality of MDR P.aeruginosa bacteremia was similar when treated with ceftolozane-tazobactam-based or colistin-based antimicrobial regimens. A higher clinical success was observed with the ceftolozane-tazobactam-based regimen compared to the colistin-based regimen. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
